Related Content
Search Google Scholar for:
More Information
Related Jobs from ScienceCareers
|
|
Science 15 March 2002: Vol. 295. no. 5562, pp. 2042 - 2046 DOI: 10.1126/science.1063814
|
|
Review
Erasing the World's Slow Stain: Strategies to Beat Multidrug-Resistant Tuberculosis
Christopher Dye,*
Brian G. Williams,
Marcos A. Espinal,
Mario C. Raviglione
Multidrug-resistant tuberculosis (MDR) is perceived as a growing
hazard to human health worldwide. Judgments about the true scale of the
problem, and strategies for containing it, need to come from a balanced
appraisal of the epidemiological evidence. We conclude in this review
that MDR is, and will probably remain, a locally severe problem; that
epidemics can be prevented by fully exploiting the potential of
standard short-course chemotherapy (SCC) based on cheap and safe
first-line drugs; and that best-practice SCC may even reduce the
incidence of MDR where it has already become endemic. On the basis of
the available, imperfect data, we recommend a three-part response to
the threat of MDR: widespread implementation of SCC as the cornerstone
of good tuberculosis control, improved resistance testing and
surveillance, and the careful introduction of second-line drugs after a
sound evaluation of cost, effectiveness, and feasibility.
Communicable Diseases, World Health Organization, CH-1211 Geneva
27, Switzerland.
*
To whom correspondence should be addressed. E-mail:
dyec{at}who.int
Read the Full Text
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
- Slow Elimination of Multidrug-Resistant Tuberculosis.
- C. Dye and B. G. Williams (2009)
Science Translational Medicine
1, 3ra8
| Abstract »
| Full Text »
| PDF »
- The epidemiological fitness cost of drug resistance in Mycobacterium tuberculosis.
- F. Luciani, S. A. Sisson, H. Jiang, A. R. Francis, and M. M. Tanaka (2009)
PNAS
106, 14711-14715
| Abstract »
| Full Text »
| PDF »
- Standardized Regimens and the Emergence of Multidrug-resistant Tuberculosis.
- K. C. Chang (2009)
Am. J. Respir. Crit. Care Med.
179, 517-518
| Full Text »
| PDF »
- Short- versus long-duration antimicrobial treatment for exacerbations of chronic bronchitis: a meta-analysis.
- M. E. Falagas, S. G. Avgeri, D. K. Matthaiou, G. Dimopoulos, and I. I. Siempos (2008)
J. Antimicrob. Chemother.
62, 442-450
| Abstract »
| Full Text »
| PDF »
- Impact of enhanced tuberculosis diagnosis in South Africa: A mathematical model of expanded culture and drug susceptibility testing.
- D. W. Dowdy, R. E. Chaisson, G. Maartens, E. L. Corbett, and S. E. Dorman (2008)
PNAS
105, 11293-11298
| Abstract »
| Full Text »
| PDF »
- Influence of Multidrug Resistance on Tuberculosis Treatment Outcomes with Standardized Regimens.
- A. Mak, A. Thomas, M. del Granado, R. Zaleskis, N. Mouzafarova, and D. Menzies (2008)
Am. J. Respir. Crit. Care Med.
178, 306-312
| Abstract »
| Full Text »
| PDF »
- Initial Drug Resistance and Tuberculosis Treatment Outcomes: Systematic Review and Meta-analysis.
- W. Lew, M. Pai, O. Oxlade, D. Martin, and D. Menzies (2008)
Ann Intern Med
149, 123-134
| Abstract »
| Full Text »
| PDF »
- Eliminating human tuberculosis in the twenty-first century.
- C. Dye and B. G Williams (2008)
J R Soc Interface
5, 653-662
| Abstract »
| Full Text »
| PDF »
- Mycobacterium tuberculosis strains disrupted in mce3 and mce4 operons are attenuated in mice.
- R. H. Senaratne, B. Sidders, P. Sequeira, G. Saunders, K. Dunphy, O. Marjanovic, J. R. Reader, P. Lima, S. Chan, S. Kendall, et al. (2008)
J. Med. Microbiol.
57, 164-170
| Abstract »
| Full Text »
| PDF »
- Competitive release and facilitation of drug-resistant parasites after therapeutic chemotherapy in a rodent malaria model.
- A. R. Wargo, S. Huijben, J. C. de Roode, J. Shepherd, and A. F. Read (2007)
PNAS
104, 19914-19919
| Abstract »
| Full Text »
| PDF »
- IL-1 Receptor-Mediated Signal Is an Essential Component of MyD88-Dependent Innate Response to Mycobacterium tuberculosis Infection.
- C. M. Fremond, D. Togbe, E. Doz, S. Rose, V. Vasseur, I. Maillet, M. Jacobs, B. Ryffel, and V. F. J. Quesniaux (2007)
J. Immunol.
179, 1178-1189
| Abstract »
| Full Text »
| PDF »
- Drug Resistance in Tuberculosis.
- G. J. Ebrahim (2007)
J Trop Pediatr
53, 147-149
| Full Text »
| PDF »
- Vaccine efficacy of an attenuated but persistent Mycobacterium tuberculosis cysH mutant.
- R. H. Senaratne, J. D. Mougous, J. R. Reader, S. J. Williams, T. Zhang, C. R. Bertozzi, and L. W. Riley (2007)
J. Med. Microbiol.
56, 454-458
| Abstract »
| Full Text »
| PDF »
- AccD6, a Member of the Fas II Locus, Is a Functional Carboxyltransferase Subunit of the Acyl-Coenzyme A Carboxylase in Mycobacterium tuberculosis.
- J. Daniel, T.-J. Oh, C.-M. Lee, and P. E. Kolattukudy (2007)
J. Bacteriol.
189, 911-917
| Abstract »
| Full Text »
| PDF »
- Molecular Epidemiology of Tuberculosis: Current Insights.
- B. Mathema, N. E. Kurepina, P. J. Bifani, and B. N. Kreiswirth (2006)
Clin. Microbiol. Rev.
19, 658-685
| Abstract »
| Full Text »
| PDF »
- The competitive cost of antibiotic resistance in Mycobacterium tuberculosis..
- S. Gagneux, C. D. Long, P. M. Small, T. Van, G. K. Schoolnik, and B. J. M. Bohannan (2006)
Science
312, 1944-1946
| Abstract »
| Full Text »
| PDF »
- Methyltransferase Erm(37) Slips on rRNA to Confer Atypical Resistance in Mycobacterium tuberculosis.
- C. T. Madsen, L. Jakobsen, K. Buriankova, F. Doucet-Populaire, J.-L. Pernodet, and S. Douthwaite (2005)
J. Biol. Chem.
280, 38942-38947
| Abstract »
| Full Text »
| PDF »
- Detection of Mutations Associated with Isoniazid Resistance in Mycobacterium tuberculosis Isolates from China.
- M. Zhang, J. Yue, Y.-p. Yang, H.-m. Zhang, J.-q. Lei, R.-l. Jin, X.-l. Zhang, and H.-h. Wang (2005)
J. Clin. Microbiol.
43, 5477-5482
| Abstract »
| Full Text »
| PDF »
- Identification of tailoring genes involved in the modification of the polyketide backbone of rifamycin B by Amycolatopsis mediterranei S699.
- J. Xu, E. Wan, C.-J. Kim, H. G. Floss, and T. Mahmud (2005)
Microbiology
151, 2515-2528
| Abstract »
| Full Text »
| PDF »
- Molecular Mechanisms by Which rRNA Mutations Confer Resistance to Clindamycin.
- J. Poehlsgaard, P. Pfister, E. C. Bottger, and S. Douthwaite (2005)
Antimicrob. Agents Chemother.
49, 1553-1555
| Abstract »
| Full Text »
| PDF »
- Rates of drug resistance and risk factor analysis in civilian and prison patients with tuberculosis in Samara Region, Russia.
- M Ruddy, Y Balabanova, C Graham, I Fedorin, N Malomanova, E Elisarova, S Kuznetznov, G Gusarova, S Zakharova, A Melentyev, et al. (2005)
Thorax
60, 130-135
| Abstract »
| Full Text »
| PDF »
- Reduced Local Growth and Spread but Preserved Pathogenicity of a {Delta}purC Mycobacterium tuberculosis Auxotrophic Mutant in Gamma Interferon Receptor-Deficient Mice after Aerosol Infection.
- N. Brown, M. Jacobs, S. K. Parida, T. Botha, A. Santos, L. Fick, B. Gicquel, M. Jackson, V. Quesniaux, and B. Ryffel (2005)
Infect. Immun.
73, 666-670
| Abstract »
| Full Text »
| PDF »
- Transmission of tuberculosis in a high incidence urban community in South Africa.
- S. Verver, R. M Warren, Z. Munch, E. Vynnycky, P. D van Helden, M. Richardson, G. D van der Spuy, D. A Enarson, M. W Borgdorff, M. A Behr, et al. (2004)
Int. J. Epidemiol.
33, 351-357
| Abstract »
| Full Text »
| PDF »
- The Prodrug Activator EtaA from Mycobacterium tuberculosis Is a Baeyer-Villiger Monooxygenase.
- M. W. Fraaije, N. M. Kamerbeek, A. J. Heidekamp, R. Fortin, and D. B. Janssen (2004)
J. Biol. Chem.
279, 3354-3360
| Abstract »
| Full Text »
| PDF »
- Facilitated Drug Influx by an Energy-uncoupled Secondary Multidrug Transporter.
- P. Mazurkiewicz, G. J. Poelarends, A. J. M. Driessen, and W. N. Konings (2004)
J. Biol. Chem.
279, 103-108
| Abstract »
| Full Text »
| PDF »
- Molecular Basis of Intrinsic Macrolide Resistance in the Mycobacterium tuberculosis Complex.
- K. Buriankova, F. Doucet-Populaire, O. Dorson, A. Gondran, J.-C. Ghnassia, J. Weiser, and J.-L. Pernodet (2004)
Antimicrob. Agents Chemother.
48, 143-150
| Abstract »
| Full Text »
| PDF »
- Unique Mechanism of Action of the Thiourea Drug Isoxyl on Mycobacterium tuberculosis.
- B. Phetsuksiri, M. Jackson, H. Scherman, M. McNeil, G. S. Besra, A. R. Baulard, R. A. Slayden, A. E. DeBarber, C. E. Barry III, M. S. Baird, et al. (2003)
J. Biol. Chem.
278, 53123-53130
| Abstract »
| Full Text »
| PDF »
- Immune Control of Tuberculosis by IFN-{gamma}-Inducible LRG-47.
- J. D. MacMicking, G. A. Taylor, and J. D. McKinney (2003)
Science
302, 654-659
| Abstract »
| Full Text »
| PDF »
- Continued Low Rates of Transmission of Mycobacterium tuberculosis in Norway.
- U. R. Dahle, P. Sandven, E. Heldal, and D. A. Caugant (2003)
J. Clin. Microbiol.
41, 2968-2973
| Abstract »
| Full Text »
| PDF »
- Mutations in the rpoB Gene of Multidrug-Resistant Mycobacterium tuberculosis Isolates from China.
- J. Yue, W. Shi, J. Xie, Y. Li, E. Zeng, and H. Wang (2003)
J. Clin. Microbiol.
41, 2209-2212
| Abstract »
| Full Text »
| PDF »
- Factors Contributing to the Occurrence of Emerging Infectious Diseases.
- F. R. Lashley (2003)
Biol Res Nurs
4, 258-267
| Abstract »
| PDF »
- Impact of DOTS compared with DOTS-plus on multidrug resistant tuberculosis and tuberculosis deaths: decision analysis.
- T. R Sterling, H. P Lehmann, and T. R Frieden (2003)
BMJ
326, 574
| Abstract »
| Full Text »
| PDF »
- Cutting Edge: Mycobacterium tuberculosis Blocks Ca2+ Signaling and Phagosome Maturation in Human Macrophages Via Specific Inhibition of Sphingosine Kinase.
- Z. A. Malik, C. R. Thompson, S. Hashimi, B. Porter, S. S. Iyer, and D. J. Kusner (2003)
J. Immunol.
170, 2811-2815
| Abstract »
| Full Text »
| PDF »
- Community-Based Therapy for Multidrug-Resistant Tuberculosis in Lima, Peru.
- C. Mitnick, J. Bayona, E. Palacios, S. Shin, J. Furin, F. Alcantara, E. Sanchez, M. Sarria, M. Becerra, M. C. S. Fawzi, et al. (2003)
N. Engl. J. Med.
348, 119-128
| Abstract »
| Full Text »
| PDF »
|
|